📰 Nasdaq Coll News
Page 4 - Nasdaq Coll News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Coll. Real-time updates on events, politics, business and more.
June 12, 2023
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) and ObsEva (NASDAQ:OBSV – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, profitability, earnings, dividends, risk and institutional ownership. Risk & Volatility Collegium Pharmaceutical has a beta of 0.81, […]
June 7, 2023
StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a hold rating to a buy rating in a research note issued to investors on Saturday morning. A number of other equities analysts have also recently issued reports on COLL. Piper Sandler dropped their price objective on Collegium Pharmaceutical from $37.00 to $35.00 in […]
June 7, 2023
Martingale Asset Management L P raised its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) by 15.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,168 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,855 shares during the quarter. Martingale Asset Management L P’s holdings in Collegium Pharmaceutical were worth […]
June 4, 2023
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) traded down 2.8% on Friday after an insider sold shares in the company. The company traded as low as $21.72 and last traded at $21.72. 19,418 shares changed hands during mid-day trading, a decline of 95% from the average session volume of 429,588 shares. The stock had previously […]
June 1, 2023
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) CEO Joseph Ciaffoni sold 31,271 shares of the business’s stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $21.90, for a total value of $684,834.90. Following the completion of the sale, the chief executive officer now directly owns 368,816 shares […]
May 20, 2023
StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a buy rating to a hold rating in a research note released on Tuesday morning. Other equities research analysts also recently issued research reports about the stock. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $35.00 in a […]
May 19, 2023
StockNews.com cut shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a buy rating to a hold rating in a report published on Tuesday. COLL has been the topic of a number of other reports. Piper Sandler decreased their target price on shares of Collegium Pharmaceutical from $37.00 to $35.00 in a research note on […]
May 17, 2023
Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday. Other equities research analysts have also recently issued research reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $35.00 target […]
May 11, 2023
StockNews.com upgraded shares of Collegium Pharmaceutical (NASDAQ:COLL – Get Rating) from a hold rating to a buy rating in a report issued on Monday morning. Several other analysts have also recently issued reports on COLL. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $35.00 in a research note on […]
May 3, 2023
Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Rating) – Stock analysts at Jefferies Financial Group issued their Q1 2023 earnings per share (EPS) estimates for Collegium Pharmaceutical in a report issued on Tuesday, May 2nd. Jefferies Financial Group analyst G. Santangelo anticipates that the specialty pharmaceutical company will post earnings of $1.00 per share for the […]